Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1ELAFIBRANOR[1] Elafibranor (Elafibranor)[1] Elafibranor (Elafibranor) 💬 [1] PPARA 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[2] 93, 94 💬
2Elafibranor 120 mg[1] Elafibranor (Elafibranor)[1] Elafibranor (Elafibranor) 💬 [1] PPARA 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[2] 93, 94 💬
3Elafibranor 80 mg[1] Elafibranor (Elafibranor)[1] Elafibranor (Elafibranor) 💬 [1] PPARA 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[2] 93, 94 💬
4Elafibranor 80mg[1] Elafibranor (Elafibranor)[1] Elafibranor (Elafibranor) 💬 [1] PPARA 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬